We provide targeted DNA sequencing allowing us to focus specific areas of interest at a reduced price and faster delivery time. Our laboratory’s technology can accommodate small blood sample sizes, making it viable alternative to a trip to the phlebotomist and reducing the impact of blood-drawing on patients’ health.
NEXT GENERATION SEQUENCING – GERMLINE MUTATION
Our Neuromuscular Amplicon Sequencing Panel targets 144 genes associated with neuromuscular disease. The test is grouped into three subclasses of neuromuscular disorders: 1) movement disorders, 2) motor neuron disorders and 3) neuromuscular disorders. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.
The test is intended to identify the variants that are associated with neuromuscular disorders. The test is intended as a pre-symptomatic genetic test to determine whether an individual with a family history of a neuromuscular disease, but no current symptoms, has the gene alterations associated with the disease. The test can also be used for post-symptomatic genetic testing to confirm variants of association to neuromuscular disorders.
All tests are performed in Ayass BioScience, LLC. Ayass BioScience, LLC (DBA Ayass Lung Clinic, PLLC) is a CLIA certified laboratory. If you have any questions about Genetic Testing Next Generation Sequencing at Ayass BioScience, LLC, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.